BackIndaptus Therapeutics Overview

Indaptus Therapeutics Other Current Liabilities

Track Indaptus Therapeutics's other current liabilities ($930K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$932999.00
63.45% YoYΔ $-1.62M vs prior year quarter

Peer average

Loading

Indaptus Therapeutics Other Current Liabilities History

Loading

Indaptus Therapeutics vs. peers: Other Current Liabilities Comparison

Loading

Indaptus Therapeutics Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Indaptus Therapeutics (INDP) FAQ

As of the most recent data (March 2026), INDP shows a other current liabilities of $930K. That compares with $2.6M in the prior-year period — down 63.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, INDP's other current liabilities is now $930K (was $2.6M) — a 63.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Indaptus Therapeutics is outperforming or lagging.

Tracking INDP's other current liabilities over time shows whether Indaptus Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $930K That compares with $2.6M in the prior-year period — down 63.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Indaptus Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $930K) with ownership activity and broader fundamentals.

Indaptus Therapeutics's other current liabilities is $930K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.